Ruijter R - Search Results

1

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. Giaccone G, et al. Among authors: ruijter r. Clin Cancer Res. 2002 Dec;8(12):3702-9. Clin Cancer Res. 2002. PMID: 12473579 Clinical Trial.

2

Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.

Kuenen BC, Giaccone G, Ruijter R, Kok A, Schalkwijk C, Hoekman K, Pinedo HM. Kuenen BC, et al. Among authors: ruijter r. Clin Cancer Res. 2005 Sep 1;11(17):6240-6. doi: 10.1158/1078-0432.CCR-04-2466. Clin Cancer Res. 2005. PMID: 16144927 Clinical Trial.

3

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE. Kuenen B, et al. Among authors: ruijter r. Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2. Clin Cancer Res. 2010. PMID: 20197484 Free article. Clinical Trial.

4

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G. Kuenen BC, et al. Among authors: ruijter r. J Clin Oncol. 2002 Mar 15;20(6):1657-67. doi: 10.1200/JCO.2002.20.6.1657. J Clin Oncol. 2002. PMID: 11896117 Clinical Trial.

5

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.

Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G. Boven E, et al. Among authors: ruijter r. Br J Cancer. 2005 May 9;92(9):1636-43. doi: 10.1038/sj.bjc.6602553. Br J Cancer. 2005. PMID: 15841080 Free PMC article. Clinical Trial.

6

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Giaccone G, et al. Among authors: ruijter r. J Thorac Oncol. 2009 Oct;4(10):1270-3. doi: 10.1097/JTO.0b013e3181b6be57. J Thorac Oncol. 2009. PMID: 20197733 Free PMC article. Clinical Trial.

7

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.

Braybrooke JP, Boven E, Bates NP, Ruijter R, Dobbs N, Cheverton PD, Pinedo HM, Talbot DC. Braybrooke JP, et al. Among authors: ruijter r. Ann Oncol. 2003 Jun;14(6):913-21. doi: 10.1093/annonc/mdg243. Ann Oncol. 2003. PMID: 12796030 Free article. Clinical Trial.

8

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.

Schöffski P, Dumez H, Ruijter R, Miguel-Lillo B, Soto-Matos A, Alfaro V, Giaccone G. Schöffski P, et al. Among authors: ruijter r. Cancer Chemother Pharmacol. 2011 Dec;68(6):1397-403. doi: 10.1007/s00280-011-1612-1. Epub 2011 Apr 5. Cancer Chemother Pharmacol. 2011. PMID: 21465314 Clinical Trial.

9

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ. van Zweeden AA, et al. Among authors: ruijter r. Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25. Cancer Chemother Pharmacol. 2018. PMID: 29696360 Free PMC article. Clinical Trial.

10

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.

Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW. Rovithi M, et al. Among authors: ruijter r. J Clin Oncol. 2019 Feb 10;37(5):411-418. doi: 10.1200/JCO.18.00725. Epub 2018 Dec 26. J Clin Oncol. 2019. PMID: 30586316 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page